臨床泌尿器科60巻11号

2006年10月発行

綜説

男性更年期障害―Late-onset hypogonadism（LOH）

著者： 伊藤直樹¹

所属機関： ¹札幌医科大学医学部泌尿器科

ページ範囲：P.783 - P.794

　要旨　Late-onset hypogonadism（LOH）は加齢に関連する臨床的，生化学的症候群であり，典型的な症状と血中testosterone値の低下により特徴づけられる。LOHの自覚症状を評価するにはAging Males' Symptoms rating scaleが有用であり，他覚所見としては骨密度，体脂肪率，筋力の測定，認知力の評価などを行う。血中testosteroneの評価は血中遊離testosteroneが適切であり，正常値は8.5pg/ml以上である。LOH症状を有し，血中遊離testosteroneが8.5pg/ml未満であればandrogen replacement therapy（ART）を考慮する。しかし，男性更年期外来受診者の半数以上は血中testosteroneは正常であることから，男性更年期障害とは加齢に伴う様々な症状を呈するheterogenousな疾患群であり，その一部にLOHがあると考える。

参考文献

1）United Nations：World Population Prospects, The 1998 Revision. New York. United Nations, 1999

2）Morales A, Heaton JPW, CarsonⅢCC：Andropause：a misnomer for a true clinical entity. J Urol 163：705-712, 2000

3）Morales A and Lunenfeld B：Androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 4：151-162, 2001

4）Morales A：Andropause（or symptomatic late-onset hypogonadism）：facts, fiction and controversies. Aging Male 7：297-303, 2004

5）Lunenfeld B, Saad F and Hoesl CE：ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males：scientific background and rationale. Aging Male 8：59-74, 2005

6）Feldman HA, Longcope C, Derby CA, et al：Age trends in the level of serum testosterone and other hormones in middle-aged men：longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 87：589-598, 2002

7）岩本晃明，柳瀬敏彦，高　栄哲，他：日本人成人男子の総テストステロン，遊離テストステロンの基準値の設定．日泌尿会誌95：751-760，2004

8）Tsujimura A, Matsumiya K, Matsuoka Y, et al：Bioavailable testosterone with age and erectile dysfunction. J Urol 170：2345-2347, 2003

9）Ferrini RL and Barrett-Connor E：Sex hormones and age：A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 147：750-754, 1998

10）Harman SM, Metter EJ, Tobin JD, et al：Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86：724-731, 2001

11）Orwoll E, Lambert LC, Marshall LM, et al：Testosterone and estradiol among older men. J Clin Endocrinol Metab 91：1336-1344. 2006

12）Mohr BA, Guay AT, O'Donnell AB, et al：Normal, bound and nonbound testosterone levels in normally ageing men：results from Massachusetts Male Ageing Study. Clin Endocrinol 62：64-73, 2005

13）Wilke TJ and Utley DJ：Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analogue RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormoen-binding globulin. Clin Chem 33：1372-1375, 1987

14）Rosner W：Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 82：2014-2015, 1997

15）Vermeulen A, Verdonck L and Kaufman JM：A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84：3666-3672, 1999

16）Smith MR：Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97（3 Suppl）：789-795, 2003

17）Shahinian VB, Kuo YF, Freeman JL, et al：Risk of fracture after androgen deprivation for prostate cancer. N Eng J Med 352：154-164, 2005

18）Khosla S, Melton Ⅲ LJ and Riggs BL：Estrogen and the male skeleton. J Clin Endocrinol Metab 87：1443-1450, 2002

19）Kawano H, Sato T, Yamada T, et al：Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100：9416-9421, 2003

20）Center JR, Nguyen TV, Sambrook PN, et al：Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 84：3626-3635, 1999

21）Khosla S, Melton Ⅲ LJ, Atkinson EJ, et al：Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women：a key role for bioavailable estrogen. J Clin Endocrinol Metab 83：2266-2274, 1998

22）Van den Beld AW, De Jong FH, Grobbee DE, et al：Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85：3276-3282, 2000

23）Greendale GA, Edelstein S and Barrett-Connor E：Endogenous sex steroids and bone mineral density in older women and men：the Rancho Bernardo Study. J Bone Miner Res 12：1833-1843, 1997

24）Khosla S, Melton Ⅲ LJ, Atkinson EJ, et al：Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86：3555-3561, 2001

25）Stanley HL, Schmitt BP, Poses RM, et al：Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 39：766-771, 1991

26）Jackson JA, Riggs MW and Spiekerman AM：Testosterone deficiency as a risk factor for hip fractures in men：a case-control study. Am J Med Sci 304：4-8, 1992

27）Barrett-Connor E, Mueller JE, Von Muhlen DG, et al：Low levels of estradiol are associated with vertebral fractures in older men, but not women：the Rancho Bernardo Study. J Clin Endocrinol Metab 85：219-223, 2000

28）Abbasi AA, Mattson DE, Duthie EH Jr, et al：Predictors of lean body mass and total adipose mass in community-dwelling elderly men and women. Am J Med Sci 315：188-193, 1998

29）Baumgartner RN, Waters DL, Gallagher D, et al：Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107：123-136, 1999

30）Couillard C, Gagnon J, Bergeron J, et al：Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men：the HERITAGE family study. J Clin Endocrinol Metab 85：1026-1031, 2000

31）Field AE, Colditz GA, Willett WC, et al：The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 79：1310-1316, 1994

32）O'Donnell AB, Travison TG, Harris SS, et al：Testosterone, dehydroepiandrosterone, and physical performance in older men：results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 91：425-431, 2006

33）Barrett-Connor E, Goodman-Gruen D and Patay B：Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 84：3681-3685, 1999

34）Muller M, Aleman A, Grobbee DE, et al：Endogenous sex hormone levels and cognitive function in aging men. Is there an optimal level? Neurology 64：866-871, 2005

35）Barrett-Connor E, Von Muhlen DG and Kritz-Silverstein D：Bioavailable testosterone and depressed mood in older men：the Rancho Bernardo Study. J Clin Endocrinol Metab 84：573-577, 1999

36）Shores MM, Moceri VM, Sloan KL, et al：Low testosterone levels predict incident depressive illness in older men：effects of age and medical morbidity. J Clin Psychiatry 66：7-14, 2005

37）Kratzik CW, Schatzl G, Lunglmayr G, et al：The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 174：240-243, 2005

38）Basar MM, Aydin G, Mert HC, et al：Relationship between serum sex steroids and aging male symptoms score and international index of erectile function. Urology 66：597-601, 2005

39）Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications：Report of WHO Consultation. Part 1：Diagnosis and Classification of Diabetes Mellitus. World Health Organization, 1999

40）メタボリックシンドローム診断基準検討委員会：メタボリックシンドロームの定義と診断基準．日内会誌94：794-809，2005

41）Makhsida N, Shah J, Yan G, et al：Hypogonadism and metabolic syndrome：implications for testosterone therapy. J Urol 174：827-834, 2005

42）Muller M, Grobbee DE, Den Tonkelaar I, et al：Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90：2618-2623, 2005

43）Laaksonen DE, Niskanen L, Punnonen K, et al：The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men：a prospective cohort study. J Clin Endocrinol Metab 90：712-719, 2005

44）Kupelian V, Page ST, Araujo AB, et al：Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91：843-850, 2006

45）Morley JE, Charlton E, Patrick P, et al：Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49：1239-1242, 2000

46）伊藤直樹，久末伸一．男性更年期障害で用いる質問紙：その有用性と限界．Urology View 2：56-62，2004

47）Heinemann LAJ, Zimmermann T, Vermeulen A, et al：A new‘aging males' symptoms’rating scale. Aging Male 2：105-114, 1999

48）Ichioka K, Nishiyama H, Yoshimura K, et al：Aging males' symptoms scale in Japanese men attending a multiphasic health screening clinic. Urology 67：589-593, 2006

49）T'Sjoen G, Feyen E, De Kuyper P, et al：Self-reffered patients in an aging male clinic：much more than androgen deficiency alone. Aging Male 6：157-165, 2003

50）Tsujimura A, Matsumiya K, Miyagawa Y, et al：Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 17：259-263, 2005

51）Bhasin S, Cunningham GR, Hayes FJ, et al：Testosterone therapy in adult men with androgen deficiency syndromes：an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91：1995-2010，2006

52）天野俊康，竹前克朗，馬場克幸，他：健康男性における遊離型テストステロンの日内変動と男性ホルモン軟膏塗布後のプロファイル．日性会誌20：13-18，2005

53）馬場克幸，中澤龍斗，中目真理子，他：男性更年期障害患者におけるテストステロン軟膏の有用性の検討．日性会誌20：19-24，2005

54）Tsujimura A, Matsumiya K, Takao T, et al：Treatment with human chorionic gonadotropin for PADAM：a preliminary report. Aging Male 8：175-179, 2005

55）Rhoden EL and Morgentaler A：Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350：482-492, 2004

56）Bhasin S, Singh AB, Mac RP, et al：Managing the risks of prostate disease during testosterone replacement therapy in older men：recommendations for a standardized monitoring plan. J Androl 24：299-311, 2003

57）Snyder PJ, Peachey H, Hannoush P, et al：Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84：1966-1972, 1999

58）Amory JK, Watts NB, Easley KA, et al：Exogenous testosterone or testosterone with finasteride increase bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89：503-510, 2004

59）Reid IR, Wattie DJ, Evans MC, et al：Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156：1173-1177, 1996

60）Crawford BAL, Liu PY, Kean MT, et al：Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88：3167-3176, 2003

61）Kenny AM, Prestwood KM, Gruman CA, et al：Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56：M266-M272, 2001

62）Ishidori AM, Giannetta E, Greco EA, et al：Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men：a meta-analysis. Clin Endocrinol 63：280-293, 2005

63）Sih R, Morley JE, Kaiser FE, et al：Testosterone replacement in older hypogonadal men：a 12 month randomized controlled trial. J Clin Endocrinol Metab 82：1661-1667, 1997

64）Steidle C, Schwartz S, Jacoby K, et al：AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88：2673-2681, 2003

65）Page ST, Amory JK, Bowman FD, et al：Exogenous testosterone（T）alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90：1502-1510, 2005

66）Boyanov MA, Boneva Z and Christov VG：Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6：1-7, 2003

67）Janowsky JS, Chavez B and Orwoll E：Sex steroids modify working memory. J Cogn Neurosci 12：407-414, 2000

68）Cherrier MM, Matsumoto AM, Amory JK, et al：Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64：2063-2068, 2005

69）Rabkin JG, Wagner GJ and Rabkin R：Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol 19：19-27, 1999

70）Pope HG Jr, Cohane GH, Kanayama G, et al：Testosterone gel supplementation for men with refractory depression：a randomized, placebo-controlled trial. Am J Psychiatry 160：105-111, 2003

71）O'Connor DB, Archer J and Wu FCW：Effects of testosterone on mood, aggression, and sexual behavior in young men：a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 89：2837-2845, 2004

72）Gray PB, Singh AB, Woodhouse LJ, et al：Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90：3838-3846, 2005

73）Snyder PJ, Peachey H, Hannoush P, et al：Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84：2647-2653, 1999

74）Cavallini G, Caracciolo S, Vitali G, et al：Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63：641-646, 2004

75）Ishidori AM, Giannetta E, Gianfrilli D, et al：Effects of testosterone on sexual function in men：results of a meta-analysis. Clin Endocrinol 63：381-394, 2005

76）Shabsigh R, Kaufman JM, Steidle C, et al：Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172：658-663, 2004

77）Rosenthal BD, May NR, Metro MJ, et al：Adjunctive use of AndroGel（testosterone gel）with sildenafil to treat erectile dysfunction in men with aquired androgen deficiency syndrome after failure using sildenafil alone. Urology 67：571-574, 2006

78）Greenstein A, Mabjeesh NJ, Sofer M, et al：Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 173：530-532, 2005

79）Anderson RA, Wallace AM, Sattar N, et al：Evidence for tissue selectivity of the synthetic androgen 7α-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 88：2784-2793, 2003

80）Gao W, Kearbey JD, Nair VA, et al：Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats：new approach for benign prostate hyperplasia. Endocrinology 145：5420-5428, 2004

81）Gao W, Reiser PJ, Coss CC, et al：Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146：4887-4897, 2005